Merck has traditionally eschewed large-scale M&A, but has been warming to the concept in recent years, with deals including its $11.5 billion takeover of Acceleron last year and its $2.75 billion ...
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback